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Macrophages are key immune cells for the initiation and devel-
opment of atherosclerotic lesions. However, the macrophage
regulatory nodes that determine how lesions progress in response
to dietary challenges are not fully understood. Liver X receptors
(LXRs) are sterol-regulated transcription factors that play a central
role in atherosclerosis by integrating cholesterol homeostasis and
immunity. LXR pharmacological activation elicits a robust anti-
atherosclerotic transcriptional program in macrophages that can be
affected by LXRα S196 phosphorylation in vitro. To investigate the
impact of these transcriptional changes in atherosclerosis develop-
ment, we have generated mice carrying a Ser-to-Ala mutation in
myeloid cells in the LDL receptor (LDLR)-deficient atherosclerotic back-
ground (M-S196ALdlr-KO). M-S196ALdlr-KO mice fed a high-fat diet ex-
hibit increased atherosclerotic plaque burden and lesions with smaller
necrotic cores and thinner fibrous caps. These diet-induced pheno-
typic changes are consistent with a reprogramed macrophage tran-
scriptome promoted by LXRα-S196A during atherosclerosis
development. Remarkably, expression of several proliferation-
promoting factors, including the protooncogene FoxM1 and its
targets, is induced by LXRα-S196A. This is consistent with increased
proliferation of plaque-resident cells in M-S196ALdlr-KO mice. More-
over, disrupted LXRα phosphorylation increases expression of phago-
cytic molecules, resulting in increased apoptotic cell removal by
macrophages, explaining the reduced necrotic cores. Finally, the mac-
rophage transcriptome promoted by LXRα-S196A under dietary per-
turbation is markedly distinct from that revealed by LXR ligand
activation, highlighting the singularity of this posttranslational mod-
ification. Overall, our findings demonstrate that LXRα phosphoryla-
tion at S196 is an important determinant of atherosclerotic plaque
development through selective changes in gene transcription that
affect multiple pathways.
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Atherosclerosis is a chronic inflammatory process and themajor pathology responsible for cardiovascular disease,
which is now the leading cause of global mortality (1). This pa-
thology results from the accumulation of lipids, immune cells,
and extracellular matrix within arterial walls, causing flow limi-
tation (2). Atherosclerotic lesions progress and may rupture and
thrombose, occluding the vessel and leading to myocardial in-
farcts or strokes. Macrophages are immune cells involved in most
key pathways for the development of atherosclerosis, including
uptake of oxidized LDL, cholesterol efflux, foam cell and fatty
streak formation, local proliferation, apoptosis, programmed
removal of dead cells or efferocytosis, necrotic core formation,
and contribution to plaque stability (2).
Liver X receptors (LXRs) are ligand-activated transcription
factors that play vital roles in cholesterol homeostasis (3) and
inflammation (4). LXRs are expressed as two isotypes, LXRα
and LXRβ, which display 78% sequence homology yet vary in
their tissue expression and regulation (5). Both LXRs are en-
dogenously activated by oxidized metabolites of cholesterol (6)
and intermediates of the cholesterol biosynthesis pathway (7), as
well as by various synthetic ligands (8). Pharmacological activa-
tion of these receptors has been demonstrated to modulate a
range of lipid and inflammatory disorders (9). With regard to
atherosclerosis, activating LXRs attenuate atherosclerosis pro-
gression (3) via promotion of cholesterol efflux through lipid-
laden macrophages present in the atherosclerotic lesions and
inhibition of vascular inflammation (4), and possibly by affecting
other aspects of lipid metabolism (10). Additionally, ligand-activated
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LXR promotes CCR7-dependent plaque regression (11). Functional
studies in macrophages further indicate that LXRα is required for
a robust antiatherosclerotic response to LXR ligands and LXRα
plays a selective role in limiting atherosclerosis in response to hy-
perlipidemia (12).
LXRα transcriptional activity can be modulated by several post-
translational modifications (5), including phosphorylation at serine
(S) 198 in the human sequence, corresponding to S196 in the mouse
ortholog. We have demonstrated that modulation of LXRα phos-
phorylation significantly modifies its target gene repertoire in
macrophage cell lines overexpressing the receptor, thereby altering
pathways known to be relevant to the development of atheroscle-
rosis (13, 14). Interestingly, we previously showed phosphorylated
S196-LXRα is present in progressive atherosclerotic lesions (14),
suggesting LXRα phosphorylation at this residue could be impor-
tant for the development of atherosclerotic plaques. However, the
specific contribution of myeloid LXRα phosphorylation to athero-
sclerosis development remains unknown.
To investigate this, we have generated a mouse model specifically
expressing a Ser-to-Ala phosphorylation mutant of LXRα in mye-
loid cells (M-S196A) in the LDL receptor (LDLR)-deficient (Ldlr-
KO) atherosclerotic background (M-S196ALdlr-KO). Disrupting
LXRα phosphorylation in myeloid cells, including macrophages,
promotes plaque burden yet modulates plaque phenotype to ac-
quire distinctive characteristics, such as smaller necrotic cores and
thinner fibrous caps encapsulating the lesions. These phenotypic
changes are consistent with a reprogrammed macrophage tran-
scriptome. Notably, cell cycle progression and proliferation path-
ways are markedly induced in M-S196ALdlr-KO macrophages,
specifically the expression of the FoxM1 transcription factor and
several of its targets. This is associated with increased lesion-
resident cell proliferation in the LXRα phosphomutant mice. In
addition, changes in the expression of various phagocytic mole-
cules result in enhanced macrophage efferocytosis, thus explaining
the reduced necrotic cores present in M-S196ALdlr-KO mice. In-
terestingly, most of the phosphorylation-sensitive genes identified
are not subject to LXR ligand regulation, and we show that global
transcriptional changes in response to impaired LXRα phos-
phorylation under dietary perturbation are markedly distinct from
those revealed by ligand activation. Overall, these findings dem-
onstrate LXRα phosphorylation at S196 determines atheroscle-
rotic plaque progression by promoting changes in local cell
proliferation, efferocytosis, and necrotic core formation.
Results
Impaired Myeloid LXRα Phosphorylation Promotes Atherosclerosis.
To investigate the impact of macrophage LXRα phosphorylation
on the development of atherosclerosis, we generated a mouse
model expressing a serine-to-alanine mutation at residue 196 in
LXRα in myeloid cells (M-S196A) on a proatherosclerotic
(LDLR-deficient or Ldlr-KO) background (M-S196ALdlr-KO) (SI
Appendix, Fig. S1A). Effective expression of a Cre-driven tar-
geting construct introducing S196A knock-in in the sense strand
was demonstrated in M-S196ALdlr-KO mice compared with
WTLdrl-KO control littermates (SI Appendix, Fig. S1B). Mice were
fed a fat-rich Western diet (WD) to accelerate plaque progression.
LXRα expression was similar in WTLdlr-KO and M-S196ALdlr-KO
mice (SI Appendix, Fig. S1 C and D). M-S196ALdlr-KO mice de-
veloped normally, and no change in body weight before, during, or
after WD feeding was observed (SI Appendix, Fig. S1 E–G). There
were no detectable changes in basal metabolic characteristics, in-
cluding total cholesterol, HDL, or LDL/very-LDL levels and the
amounts of triglycerides, free fatty acids, and insulin in the plasma
of M-S196ALdlr-KO mice compared with WTLdlr-KO mice (SI Ap-
pendix, Fig. S2). Interestingly, M-S196ALdlr-KO mice showed a sig-
nificant increase in atherosclerosis plaque burden in their aortas as
measured by en face Oil Red O staining (Fig. 1A) and aortic root
plaque coverage (Fig. 1 B and C). However, this was not associated
with changes in the levels of CD68+ cells in the lesions (Fig. 1D).
Changes in LXRα Phosphorylation at Ser196 Reprogram Global
Macrophage Gene Expression in the Context of Diet-Induced
Atherosclerosis. To explore in more detail the pathways un-
derlying the changes observed in atherosclerosis development, we
investigated the transcriptomic profiles of macrophages differenti-
ated from the bone marrow of mice exposed to the WD. RNA-
sequencing (RNA-seq) analysis revealed significant genome-wide
changes in transcript levels (Fig. 2 A and B). LXRα-S196A signifi-
cantly induced (n = 460) or reduced (n = 210) gene expression. The
impact of LXRα-S196A on the basal macrophage expression of
well-established LXR targets varied: While Srebf1 and Abcg1 levels
were not affected, other targets, such as Abca1 and Apoe, were
significantly reduced (SI Appendix, Fig. S3A). Hallmark pathway
analysis identified G2/M checkpoint and E2F targets to be markedly
Fig. 1. M-S196ALdlr-KO mice develop increased atherosclerosis on a WD. (A,
Left) Representative images of en face Oil Red O-stained whole aortas (n =
8–11 per group). (Original magnification: 8×.) (A, Right) Quantification of
stained areas as percent plaque coverage for each genotype. (B) H&E-stained
aortic roots (n = 9–10 per group). (Scale bars: 500 μm.) (C) Quantification of
stained areas as percent plaque coverage for each genotype. (D) CD68 staining
of aortic roots (n = 7–8 per group). Data are mean ± SEM (*P < 0.05, relative to
WTLdlr-KO mice). NS, not significant.
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Fig. 2. Changes in LXRα phosphorylation reprogram macrophage gene expression. (A) Volcano plot of log2 ratio vs. P value of differentially expressed genes
comparing 12-wk-old, WD-fed M-S196ALdlr-KO and WTLdlr-KO bone marrow-derived macrophages (n = 3 per group). The blue line indicates an adjusted P value
threshold of 0.04 (Wald test for logistic regression). (B) Clustered heat map of RNA-seq gene counts in WD-fed macrophages (n = 3 mice per group). (C) Gene
set enrichment analysis showing enriched pathways in M-S196ALdlr-KO macrophages derived from hallmark gene sets. (D) Fold change of RNA-seq gene counts
in M-S196ALdlr-KO compared with WTLdlr-KO macrophages (set as 1) (n = 3 per genotype) for the top induced genes (≥twofold expression, P ≤ 0.01) involved in
cell proliferation. (E) Heat map of RNA-seq gene counts of immune response genes down-regulated by S196A in WD-fed macrophages (n = 3 mice per group).
(F) Heat map of RNA-seq gene counts of chemokine receptor (Top) and chemokine ligand genes (Bottom) showing differentially expressed genes in S196A
WD-fed macrophages (n = 3 mice per group). For all heat maps, blue and orange depict up-regulated and down-regulated genes, respectively, and only genes
showing ≥1.3-fold change with P ≤ 0.01 are shown.
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Fig. 3. Impaired macrophage LXRα phosphorylation induces FoxM1 expression and increases plaque cell proliferation. (A) Fold-change of RNA-seq gene counts in
WD-fed M-S196ALdlr-KO compared with WD-fed WTLdlr-KO macrophages (set as 1) for FoxM1 and FoxM1 target genes with ≥1.3-fold expression (P ≤ 0.01; n = 3 per
genotype). LXR occupancy and H3K27 acetylation (HK27Ac) at the Srebf1 reported LXRE (B) and FoxM1 (C) and Cenpf (D) identified DR4 sequences (LXR-binding sites)
in bone marrow-derived macrophages from M-S196ALdlr-KO and WTLdlr-KO WD-fed mice are shown. Data shown are normalized to input compared with a region
within in a gene desert (Neg S) as a negative control. One representative experiment of three (each using n = 2mice per genotype) is shown. (E) Representative images
of plaques exhibiting Ki67+ nuclei. L, lumen; P, plaque. (Scale bars: 250 μm.) (F) Quantification of Ki67+ nuclei in WD-fed WTLdlr-KO and M-S196ALdlr-KO plaques (n = 6–
10 mice per group). **P ≤ 0.01. (G) Flow cytometry histograms of Ki67 expression in F4/80+macrophages (Left) and bar chart of percentage of Ki67+ cells in WTLdlrKO
andM-S196ALdlr-KO macrophages exposed to 20 μMFDI-6 inhibitor (Right). Data shown are representative of three independent experiments (n = 2mice per genotype
each). (H) Histogram (Left) and bar chart of percentage of Ki67+M-S196ALdlr-KO macrophages in response to indicated concentrations of FDI-6 (Right). Data shown are
representative of three independent experiments (n = 2 mice per genotype each). (I) RT-qPCR analysis of FoxM1 target genes in WTLdlr-KO and M-S196ALdlr-KO
macrophages. Normalized data are shown relative to WTLdlr-KO as mean ± SD (n = 3) compared with WT-DMSO (a) and with M-S196A-DMSO (b).
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enriched, indicating cell cycle and cell proliferation pathways are
induced in the mutant-expressing macrophages (Fig. 2C and SI
Appendix, Fig. S4 A and B). This was further confirmed by reac-
tome pathway analysis (SI Appendix, Table S1). Several genes
involved in these processes were regulated over twofold, including
cell proliferation marker Mik67 or Ki67 (4.58-fold, P = 3.46E-43)
(Fig. 2D). Concomitant to these changes in cell proliferation
genes, there was a substantial reduction in the expression of genes
associated with the immune response (Fig. 2 C and E and SI
Appendix, Fig. S4C and Table S2). We observed opposing changes
in the expression of chemokine receptors involved in monocyte
trafficking to atherosclerotic lesions and some of the chemokines
they bind to (15) (Fig. 2F). For example, expression of the che-
mokine receptors Ccr1 (1.43-fold, P = 0.004), Ccr2 (1.73-fold, P =
3.8 × 10−15), and Cx3cr1 (1.8-fold, P = 0.0008) was increased,
whereas Ccr5 (0.55-fold, P = 6.19 × 10−17) expression was di-
minished in LXRα-S196A macrophages compared with WT
macrophages. Such differential expression of chemokine receptors
and their ligands may explain the lack of change in the overall
number of CD68+ cells retained in the plaques of M-S196ALdlr-KO
mice. Furthermore, there was no difference in the number of
circulating monocytes between genotypes (SI Appendix, Fig. S1H).
M-S196A Induces Expression of FoxM1 and Lesion-Resident Cells.
Examination of the RNA-seq datasets revealed LXRα-S196A
cells expressed almost threefold (P = 7.76E-14) more proto-
oncogene FoxM1 compared with macrophages expressing WT
LXRα (Fig. 3A and SI Appendix, Fig. S4D). This was also the case
for several FoxM1 target genes (16) (Fig. 3A and SI Appendix, Fig.
S4D). While LXRα activation was previously shown to inhibit cell
proliferation via inhibition of FoxM1 in hepatic carcinoma cells
(17), its regulation in macrophages has never been documented.
LXRs modulate gene transcription by heterodimerizing with the
retinoid X receptor (RXR) and binding to specific DNA sequences
termed LXR response elements (LXREs) in the transcriptional
regulatory regions of their target genes (18). Similar to the well-
known Srebf1 LXR target (Fig. 3B), specific LXRα occupancy was
observed at the FoxM1 gene in macrophages at different sites (Fig.
3D), further indicating that FoxM1 is an LXRα target in these cells.
These sites were initially identified by ChIP-sequencing analysis (SI
Appendix, Fig. S5A) and in silico by sequence similarity to reported
LXREs. We also confirmed that, unlike FoxM1, genes upstream of
this gene were not significantly influenced by the expression of
LXRα-S196A in macrophages (SI Appendix, Fig. S5B). Contrary to
Srebf1, which is not affected by LXRα-S196A expression, LXRα
occupancy, as well as H3K27 acetylation, at FoxM1 and at one of its
targets, Cenpf, was modestly enhanced in macrophages expressing
the phosphomutant receptor, suggesting this may be one of the mech-
anisms by which LXRα-S196A influences the expression of these
genes. The enhanced levels of several promitotic genes suggested
cell proliferation could be altered in M-S196ALdlr-KO macro-
phages. Indeed, macrophages expressing the LXRα-S196A mutant
showed about a 20% increase in proliferation in culture measured
as Ki67 levels (SI Appendix, Fig. S5 C and D). Recent studies have
highlighted the important role local macrophage proliferation
plays in lesion development (19). Consistent with a significant in-
crease in the regulation of FoxM1 and other genes involved in cell
cycle pathways, increased proliferation of lesion-resident cells as
measured by Ki67 staining was observed in the atherosclerotic plaques
of M-S196ALdlr-KO mice (Fig. 3B), which was associated with
increased nuclei content (SI Appendix, Fig. S6B) compared with
WTLdlr-KO mice. Notably, pharmacological inhibition of FoxM1
using the specific inhibitor FDI-6 (20, 21) reduced the enhanced M-
S196ALdlr-KO macrophage proliferation observed (Fig. 3 G and
H) and consistently reduced FoxM1 target gene expression (Fig.
3I), confirming that FoxM1 up-regulation mediates, at least in
part, some of the increased macrophage proliferation observed in
M-S196ALdlr-KO mice. This strongly suggests that FoxM1-dependent
enhanced local proliferation in the plaques could contribute to
increased plaque size exhibited by M-S196ALdlr-KO mice, as has
been postulated (22–24).
M-196ALdlr-KO Mice Display Phenotypic Changes in Their Necrotic
Cores and Fibrous Caps. The observed changes in gene expression
suggest a complex interaction of pathways involved in the pro-
gression of atherosclerosis. Unexpectedly, despite their larger size,
size-matched atherosclerotic lesions in M-S196ALdlr-KO mice dis-
play smaller necrotic cores (Fig. 4A). Programmed cell removal or
efferocytosis has been shown to strongly impact the formation of
necrotic cores in advanced plaques (25). In agreement with this,
macrophage engulfment of apoptotic cells was significantly increased
(Fig. 4B and SI Appendix, Fig. S6C). Further interrogation of
the LXRα-S196A–regulated transcriptome showed differential
expression of several pro- and antiphagocytic molecules (Fig. 4C
and SI Appendix, Fig. S3B). These include Ccr2 (1.73-fold, P =
3.8 × 10−15), Gpr132 (1.64-fold, P = 1.73 × 10−10), Itgb3 (1.59-fold,
P = 0.007), andMfge8 (1.37-fold, P = 7.46 × 10−5), which are known
to promote efferocytosis (25), as well as molecules known to render
apoptotic cells resistant to efferocytosis, such as Cd47 (26) (0.75-fold,
P = 0.0001) and Tnf (0.71-fold, P = 0.0004) in M-S196ALdlr-KO
macrophages. This is consistent with the enhanced efferocytosis
observed in these cells. Another important morphological feature of
atherosclerotic lesions influenced by macrophages is the thinning of
the protective collagenous scar surrounding them or fibrous caps
(2). Interestingly, M-S196ALdlr-KO lesions show a reduced fibrous
cap thickness with overall smaller fibrous cap areas (SI Appendix, Fig.
S6 D and E). This could result from the diminished expression of
several collagen genes, including Col1a1 (0.6-fold, P = 9.3 × 10−04),
Col1a2 (0.7-fold, P = 9.9 × 10−03), Col3a1 (0.6-fold, P = 4.0 × 10−03),
Col5a1 (0.6-fold, P = 3.4 × 10−03), and Col6a1 (0.5-fold, P =
4.2 × 10−05), and increased levels of matrix-degrading molecules,
Fig. 4. M-S196ALdlr-KO mice show decreased plaque necrotic cores and in-
creased efferocytosis capacity. (A, Left) H&E-stained mature plaques depict
necrotic core (NC; n = 4–6 per group); representative images are shown. (A,
Right) Quantification of H&E-stained areas for each genotype. (Scale bars:
250 μm.) (B) Engulfment of apoptotic Jurkat cells (*P ≤ 0.05; n = 6 per
group). (C) Fold change of RNA-seq gene counts in WD-fed M-S196ALdlr-KO
compared with WD-fed WTLdlr-KO macrophages (set as 1) for pro- and anti-
phagocytic genes (n = 3 per genotype).
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D
ow
nl
oa
de
d 
at
 R
O
YA
L 
VE
TE
RI
NA
RY
 C
O
LL
EG
E 
on
 N
ov
em
be
r 5
, 2
01
9 
such as Mmp8 (1.57-fold, P = 6.1 × 10−10) andMmp12 (1.48-fold,
P = 8.8 × 10−6). Overall, these data highlight the complex pheno-
typic changes present in atherosclerotic lesions resulting from
changes in LXRα phosphorylation.
Disrupted LXRα Phosphorylation at Ser196 Alters Ligand Responses in
Macrophages. Our findings indicate that in the context of an ath-
erogenic diet, changes in LXRα phosphorylation modulate the
macrophage transcriptome and promote the atherosclerotic plaque
burden. To further understand the magnitude of the transcrip-
tional changes imposed by the LXRα phosphorylation mutant, we
next examined whether WT- and S196A-expressing macrophages
respond differently to an LXR ligand and explored the differences
in global transcript changes between ligand activation and reduced
LXRα phosphorylation. RNA-seq analysis was performed on bone
marrow-derived macrophages from M-196ALdlr-KO mice exposed
to the WD for 12 wk and cultured in the presence of vehicle or
LXR ligand GW3965. GW ligand activation promoted changes in
macrophage gene expression that were different in cells expressing
the S196A mutant compared with WT macrophages (SI Appendix,
Fig. S7 A–C). Gene set enrichment analysis revealed the pathways
subject to changes in LXRα phosphorylation in the presence of the
LXR ligand are similar to those seen in the absence of GW (SI
Appendix, Fig. S7D). For instance, genes involved in nuclear di-
vision and cell cycle regulation remained strongly induced by
LXRα-S196A, further emphasizing the importance of LXRα
phosphorylation in the modulation of these pathways. Remarkably,
it became apparent that while a small subset of genes was differen-
tially regulated by the mutant only in the context of the ligand
(94 induced and 50 reduced compared with WT cells), most differ-
ences in gene expression were observed in the absence of ligand (Fig.
5 A and B). Additionally, our datasets showed that ligand responses
(either induction or repression) were similar in both WT- and
mutant-expressing macrophages for a subset of genes, but not for
others (Fig. 5C and SI Appendix, Fig. S8). Further analysis revealed
that both the magnitude of the response and the identity of the genes
were strikingly different between the response to the ligand (regu-
lation by GW in either WT or S196A cells) and to phosphorylation
(modulation by LXRα-S196A compared with WT cells) (SI Appen-
dix, Fig. S7 E and F). This highlights the significance of S196 phos-
phorylation in rewiring the LXR-modulated transcriptome.
Finally, we investigated whether this dichotomy between ligand-
and phosphorylation-induced responses was apparent in the reg-
ulation of the phosphorylation-sensitive gene FoxM1 and some of
its target genes. FoxM1 was not significantly affected by exposure
to the LXR ligand inWTLdlr-KO cells (Fig. 5 D and E). By contrast,
GW3965 activation markedly reduced FoxM1 mRNA levels in M-
S196ALdlr-KO macrophages (Fig. 5 D and E). This regulatory
pattern was recapitulated by most FoxM1 targets examined. In
addition, established transcriptional regulators of FoxM1 were
strongly (Top2a, Rad51, and Check2) or moderately (Melk) in-
duced in M-S196ALdlr-KO cells in unstimulated conditions com-
pared with WTLdlr-KO cells (Fig. 5F). Consistent with the known
antiproliferative effects of LXR ligands, the expression of these
genes was strongly attenuated by GW3965, although this occurred
preferentially in the mutant cells. Other LXRα phosphorylation-
sensitive genes implicated in cell cycle progression mimic this
mode of regulation (SI Appendix, Fig. S7G).
Overall, our findings suggest that LXRα phosphorylation at
Ser196 is a powerful means of regulating LXRα transcriptional
activity that has important consequences for macrophage biology
and for the progression of a metabolic, inflammatory, and pro-
liferative disease, such as atherosclerosis.
Discussion
The macrophage regulatory nodes that determine how the ath-
erosclerotic lesion progresses in response to dietary challenges
are not fully understood. LXRs have key roles in the regulation
of macrophage lipid homeostasis and inflammation, and, as such,
they strongly modulate the progression of metabolic diseases,
such as atherosclerosis (3). The importance of these receptors in
disease development has been mainly gleaned from studies
evaluating the consequences of their pharmacological or genetic
manipulation. However, it remained unknown whether alterna-
tive modulation of the activity of these receptors, for instance, by
altering posttranslational modifications of the receptor, could
shape the proatherogenic responses of fat-rich diets, thus alter-
ing disease development. We previously showed LXRα is phos-
phorylated in cholesterol-loaded macrophages and in progressive
atherosclerotic plaques (13). We have now explored the impact
of LXRα phosphorylation on atherosclerosis development by
expressing an LXRα Ser196-to-Ala mutant, previously shown to
disrupt LXRα phosphorylation (13), specifically in myeloid cells
on the LDLR-null background (M-S196ALdlr-KO).
LXRα-S196A expression in cells of the myeloid lineage, including
macrophages, increases atherosclerotic plaque burden (Fig. 1 and
SI Appendix, Fig. S9). This is consistent with an enhanced number of
proliferating lesion-resident cells (Fig. 3E) in M-S196ALdlr-KO mice
and the up-regulation of genes driving cell cycle progression in
macrophages, particularly at the G2/M checkpoint, accounting for
up to 15% of the total changes in gene expression exerted by the
phosphorylation mutant (Fig. 2C). During the past decade, estab-
lished paradigms of atherosclerotic plaque formation and progres-
sion have been revisited, and local proliferation of macrophages has
been demonstrated to be an important driver of atherosclerosis
development in advanced atherosclerotic plaques (22, 24, 27).
However, the specific players modulating macrophage proliferation
in the context of atherosclerosis remain poorly understood. Pro-
liferation of lesional macrophages has been linked to up-regulation
of the scavenger receptor Msr1 (22, 28), but a defined mechanism
has remained elusive. Our findings now indicate that modulation of
LXRα phosphorylation plays an important role in this process.
LXRs are known modulators of cell proliferation in other dis-
ease conditions where cell proliferation is critical, including cancer
(29). For instance, LXR activation inhibits proliferation of B and
T cells and macrophages (30–32) as well as several cancer cell lines,
including prostate (LNCaP) (33), breast (MCF7) (34), and colon
(HTC111) (35). Identified antiproliferative mechanisms by classic
LXR agonists appear to be independent of the lipogenic activity of
LXR (34) but, rather, linked to β-catenin activity (35), cyclins (33),
and sterol metabolism (32). In contrast to these inhibitory effects,
LXR activation was recently reported to enhance proliferation of
neural progenitor cells in a MAPK/extracellular signal-regulated
kinase pathway-dependent manner (36). Inverse agonism of LXR
with a novel synthetic inverse agonist has also shown promise as a
potential cancer treatment through inhibition of lipogenesis, gly-
colysis, and by regulating the expression of key glycolytic and
lipogenic genes (29). However, in our study, LXR is shown to
target cell cycle promoting factors in an atherosclerotic context.
The underlying mechanisms explaining the reported LXR
antiproliferative actions may be cell-specific. The inhibitory ef-
fects of LXR ligands on macrophage colony-stimulating factor–
stimulated macrophage proliferation involve down-regulation of
the cyclin-dependent kinase regulators cyclin D1 (Ccnd1) and B1
(Ccnb1) (31). Both cyclins are inhibited by LXRα through the
transcriptional repression of FoxM1 in hepatic carcinoma cells
(17). Conversely, LXR antagonism with a sulfated oxysterol
promotes hepatic proliferation, in part, through the induction of
FoxM1 (37). FoxM1 is an essential proliferation-associated
transcription factor found overexpressed in numerous solid tu-
mors (38–41). Its expression is restricted to actively dividing cells,
and it is regulated in a cell cycle-dependent manner by a wide
range of proliferative signals (42). FoxM1 levels are induced in
the G1 phase, maintained throughout the S phase, and reach
maximum expression in the G2/M phase (43–46). We now
demonstrate that chronic disruption of LXRα phosphorylation in
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macrophages enhances FoxM1 expression and several of FoxM1-
associated regulators and targets driving cell cycle progression
(16) (Fig. 3A and SI Appendix, Fig. S4D). We have now identified
multiple LXRα-binding sites at the FoxM1 locus, confirming
FoxM1 is an LXR target in macrophages (Fig. 3C). LXRα oc-
cupancy and H3K27 acetylation are modestly enhanced at some
of these sites in cells expressing the LXRα phosphomutant, in-
dicating this is likely one of the mechanisms underlying enhanced
FoxM1 expression in these cells. It is possible that expression of
the S-to-A mutant could affect the structure/function of LXRα
Fig. 5. Macrophage transcriptional reprogramming in response to changes in LXRα phosphorylation is fundamentally different from ligand activation re-
sponses. (A and B) RNA-seq analysis on M-S196ALdlr-KO and WTLdlr-KO macrophages from WD-fed mice exposed to 1 μM GW3965 (GW) (n = 3 per group). Venn
diagrams of genes induced (A) or reduced (B) in S196A compared with WT cells are shown. (C) Comparison of ligand responses in M-S196ALdlr-KO and WTLdlr-KO
macrophages. (Middle) Venn diagram of genes induced (UP) or reduced (DOWN) by GW in WT LXRα cells compared with differentially expressed genes (DEGs)
in S196A vs. WT in vehicle-treated (DMSO) conditions. Bar graphs show fold changes in gene expression for genes induced (Top) or reduced (Bottom) by GW
that are also differentially regulated by S196A. #, not significant. (D) Clustered heat map of RNA-seq gene counts for FoxM1 and its target genes in mac-
rophages from WD-fed mice (n = 3 per group) treated as indicated. (E) RT-qPCR analysis of FoxM1 and its target genes in WD-fed WTLdlr-KO and M-S196ALdlr-KO
macrophages. Normalized data are shown relative to WTLdlr-KO macrophages as mean ± SD (n = 3) [P ≤ 0.001 compared with WT-DMSO (a), P ≤ 0.001 compared
with S196A-DMSO (b), and P ≤ 0.001 compared with WT-GW (c)]. (F) mRNA expression of FoxM1 regulators. Data and statistical analysis are as in E.
E6562 | www.pnas.org/cgi/doi/10.1073/pnas.1721245115 Gage et al.
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unrelated to its impact on the phosphorylation of the receptor.
Nevertheless, we have previously shown by molecular modeling
that phosphorylated and nonphosphorylated receptors can adopt
different structures that could influence protein–protein in-
teractions, ultimately modulating LXRα function (14). Im-
portantly, induced FoxM1 levels are associated with increased
lesional cell proliferation (Fig. 3E) and cell content (SI Ap-
pendix, Fig. S6B), consistent with larger atherosclerotic le-
sions. Among FoxM1 regulators, Bub1b [or Bub receptor 1
(BubR1), increased 1.9-fold, P = 1.26 × 10−6 in the LXRα-
S196A–expressing macrophages] has been shown to alter athero-
sclerosis, as impaired expression of BubR1 results in decreased
macrophage proliferation and attenuated atherogenesis (47). Fur-
thermore, LXRα-S196A macrophages show decreased mRNA
expression of the FoxM1 inhibitor SASH1 (48) (0.8-fold, P =
1.33 × 10−4), which has been implicated in the development of
atherosclerosis in people who smoke, through its upregulation in
monocytes. Notably, we now provide evidence that specific in-
hibition of FoxM1 reduces proliferation of LXRα-S196A mac-
rophages, confirming the relevance of this pathway. Overall, our
findings further highlight the importance of this set of mole-
cules in atherosclerosis progression.
Importantly, we show evidence that reduced LXRα phos-
phorylation during atherosclerosis development reprograms the
macrophage transcriptome (Fig. 2). Global gene expression
analysis revealed that in these cells, most genes are sensitive to
the expression of the LXRα phosphomutant in the absence of
LXR ligand stimulation, with only an additional 82 genes being
modulated by the mutant in the presence of the GW3965 ligand
compared with the 670 LXRα phosphorylation-sensitive genes
under basal conditions (SI Appendix, Fig. S7 E and F). This
suggests that modulation by LXRα-S196A expression is different
from the regulation by ligand activation of the receptor. Indeed,
comparison of the various datasets evidenced that the tran-
scriptomic rewiring in response to impaired LXRα phosphory-
lation in the mutant cells is remarkably distinct and does not
merely phenocopy ligand responses (Fig. 5C and SI Appendix,
Fig. S8 C and D), thus highlighting the importance of this post-
translational modification in modulating the activity of LXRα in
the context of a metabolic and inflammatory disease. An example
of this is the regulation of FoxM1 expression and its regulated
pathways, which are induced in LXRα-S196A–expressing cells
(Fig. 3A and SI Appendix, Fig. S4D). Previous reports have linked
LXRα activation with FoxM1 repression in hepatic carcinoma
cells (17). We observed that FoxM1 inhibition by GW3965 is re-
capitulated in macrophages from mice exposed to a high-fat diet
that are developing atherosclerotic plaques (Fig. 5 D and E).
However, this is preferentially observed in the LXRα phos-
phorylation mutant-expressing cells. In fact, most FoxM1 targets
and modulators, as well as other factors involved in the G2/M
cell cycle transition, mirror this pattern of regulation (Fig. 5 E
and F and SI Appendix, Fig. S7G). This suggests that in macro-
phages, the antiproliferative effects of LXR ligands are enhanced
when LXRα phosphorylation is disrupted. Intriguingly, these
transcriptomic changes are observed in cells that have been differ-
entiated and cultured in vitro from precursor cells exposed to the
proatherosclerotic environment in the bone marrow of WD-fed
mice and could be the result of epigenetic changes influenced
by the diet. Indeed, there are reports showing a distinct metabolic
environment (e.g., in type 2 diabetes) can epigenetically imprint
bone marrow progenitor cells that can derive into a “prepro-
grammed” macrophage state associated with changes in gene
expression (49). Outside the scope of this study, future investigations
will help establish changes in the epigenome of LXRα-S196A–
expressing cells and how they affect metabolic, proliferative,
and inflammatory pathways.
The observed changes in gene expression are likely to result
from a combination of factors, including differential binding to
DNA (as shown in Fig. 3D) and possibly variations in the in-
teraction with cofactors. Indeed, we have previously described
that differential NCoR binding to the LXR phosphomutant is
important for the variation in the expression of certain targets
(13). In addition, using molecular modeling, we have shown how
LXRα in its unphosphorylated state may impact cofactor inter-
actions by exposing an alternative surface for protein interaction
(14). Thus, a mutation disrupting phosphorylation would be
expected to mimic these interactions in vivo, which could also
partly explain the observed changes in gene expression. Based on
this molecular modeling, it is currently unclear how the change in
LXR phosphorylation at this serine residue could impact DNA
binding. The S198 residue does not contact directly with DNA or
the RXRα DNA-binding domain. However, this was examined
for one particular LXRE, and it may likely vary at different
LXRE/DNA sequences, thus explaining the gene-specific effects
observed when the phosphomutant is expressed. Future investi-
gations beyond the scope of this study comparing global WT and
phosphomutant LXR DNA-binding profiles will be able to
provide further insight into the molecular mechanisms behind
the observed differences in gene expression.
Beyond changes in cell proliferation, the enhanced plaque bur-
den in M-S196ALdlr-KO mice is likely the result of the complex
modulation of additional pathways relevant for atherosclerosis de-
velopment. LXRα promotes the expression of factors important for
macrophage efferocytotic capacity, such as the MerTK receptor for
apoptotic cells (50), which can influence the formation of the ne-
crotic core and plaque stability (51). Despite the overall increase in
atherosclerosis, we found that size-matched advanced plaques from
M-S196ALdlr-KO mice exhibited significantly reduced necrotic cores
(Fig. 4A) consistent with the increased capacity of M-S196ALdlr-KO
macrophages to engulf apoptotic cells (Fig. 4B and SI Appendix, Fig.
S6C). Transcriptomic profiling revealed that in addition to the re-
duced expression of Mertk and its ligand Gas6, several genes
known to promote phagocytosis were significantly up-regulated in
M-S196ALdlr-KO cells, including the prophagocytotic receptors Ccr2
(52), Gpr132 (53), and Itgb3 (54) and the bridging molecule Mfge8
(55) (Fig. 4C and SI Appendix, Fig. S3B). This differential expres-
sion could explain the increased phagocytic ability of the LXRα
phosphomutant-expressing macrophages (Fig. 4B).
With regard to the signals that may regulate LXRα phosphory-
lation in the context of atherosclerosis progression, we previously
showed that LXRα is phosphorylated at this same residue both in
response to cholesterol loading in cultured macrophages and in
foam cells within atherosclerotic plaques from animal models fed a
high-fat diet (13). A possible candidate could be desmosterol (a
cholesterol precursor and the last intermediate in the Bloch bio-
synthesis pathway), which accumulates in macrophage foam cells
and atherosclerotic plaques (7) and acts as an endogenous LXR
ligand modulating its target gene expression (7, 56). Desmosterol
promotes phosphorylation of LXRα in macrophages in culture (SI
Appendix, Fig. S10) and could be one of the many signals that affect
LXRα phosphorylation in an atherosclerotic environment, although
it is likely that a combination of them is responsible for ultimately
promoting this modification. It is possible that endogenous cues
preventing LXRα phosphorylation, thus mimicking the Ser-to-
Ala mutation, may alter cell proliferation and phagocytosis in a
similar manner. However, they are also likely to exert other
(similar or opposing) effects to other transcription factors or
signaling molecules. Future studies will aim to further identify
endogenous signals modulating LXRα phosphorylation in the
context of atherosclerosis.
In summary, we have shown that disrupting LXRα phos-
phorylation in cells of the myeloid lineage affects the develop-
ment of atherosclerosis that could be explained through altered
cell proliferation and efferocytosis. We also show that chroni-
cally modulating LXRα phosphorylation reprograms gene reg-
ulation in macrophages under basal conditions and significantly
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affects their response to ligand stimulation. These findings add
to our fundamental knowledge of how LXRα activity can be
regulated and introduce functional consequences of its modi-
fication by phosphorylation, which should be heeded to ma-
nipulate these receptors for the design of novel cardiovascular
therapies.
Materials and Methods
Analysis of Murine Atherosclerosis Development.WTLdlr-KO and M-S196ALdlr-KO
mice were generated as described in SI Appendix, SI Materials and Methods.
All animal procedures and experimentation were approved by the UK’s
Home Office under the Animals (Scientific Procedures) Act 1986, PPL 1390
(70/7354). Eight-week-old WTLdlr-KO and M-S196ALdlr-KO male mice were fed
a WD ad libitum (20% fat, 0.15% cholesterol; no. 5342 AIN-7A; Test Diet
Limited) for 12 wk. Murine atherosclerosis and lesion characterization were
performed as described in SI Appendix, SI Materials and Methods.
Cell Culture and in Vitro Experiments. Bone marrow-derived macrophages
were prepared as reported by Pineda-Torra et al. (57). Peritoneal macro-
phages and Jurkat cells were prepared as described in SI Appendix, SI Mate-
rials and Methods. An efferocytosis assay and flow cytometry were performed
as described in SI Appendix, SI Materials and Methods.
Gene Expression Analysis. RNA quantification, RT-qPCR, and RNA sequencing
and analysis were performed as described in SI Appendix, SI Materials
and Methods.
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